Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04601116 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The MASTER Study (MAmmary Cancer STatin ER Positive Study)

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 14, 2021 (before its estimated January 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Primary completion date: Sep 1, 2024 to Jan 1, 2025 · Completion date: Sep 1, 2034 to Jan 1, 2035 · 1 morev2 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Primary completion date: Sep 1, 2024 to Jan 1, 2025
    • Completion date: Sep 1, 2034 to Jan 1, 2035
    • Start date changed from estimate of Oct 21, 2020 to Jan 4, 2021
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Given the compelling evidence supporting a protective effect of statins on breast cancer recurrence, calls for prospective clinical trials have been expressed. In this trial - the MASTER trial - we hypothesize that the addition of statin treatment to the current breast cancer treatment will improve the prognosis of women with early breast cancer. This trial is designed as follows: a randomized, multicenter, double-blind, placebo-controlled comparison of standard (neo)adjuvant therapy plus placebo versus standard (neo)adjuvant therapy plus atorvastatin in patients with early breast cancer.
Trial Details
NCT Number NCT04601116
Lead Sponsor Aarhus University Hospital
Collaborators: Rigshospitalet, Denmark, Hospital of Southern Jutland, University of Copenhagen, Bornholms Hospital, Naestved Hospital, Vejle Hospital, Odense University Hospital, Nordsjaellands Hospital, Aalborg University Hospital, Herning Hospital
Conditions Breast Cancer Female, Estrogen Receptor Positive Tumor
Enrollment 3,360 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov